Prof Simon Harrison speaks to ecancer about MRD-driven strategies and novel immunotherapies for multiple myeloma.
He talks about his presentation at MyKE Myeloma 2021.
Initially, Prof Harrison talks about the MRD-driven strategies in NDMM.
He then explains some of the novel immunotherapies for multiple myelomas.
Prof Harrison concludes by discussing bispecific antibodies, CAR T therapies and ADCs.